New Ozempic Rival Achieves 25% Weight Loss in Phase 3 Trial
Audio narration · Coming soon
A new drug competing with Ozempic has demonstrated a 25% weight loss at its highest dose during a Phase 3 clinical trial. This development could offer a significant new option for patients struggling with weight-related health issues.
Why this matters
PRISM scored this story 60/100 for interest.
Originally published by gnews